Clinical trials: Education Training
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Asthma
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical…
- Trial name
- NCT04813354
- Testing
- ELLIPTA, BREEZHALER
- Where
- 3 sites in Netherlands
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Dementia
Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system (MHS) will offer a caregiver training product in adjunct.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Assistive Technology
- Trial name
- NCT05527405
- Testing
- The MapHabit System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- MapHabit, Inc.
Pulmonary Disease, Chronic Obstructive
A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, multi-centre, open-label, placebo-device, cross-over study, with a 2x2 complete block design in subjects with chronic obstructive pulmonary disease (COPD) to assess the benefits of delivering triple therapy…
- Trial name
- NCT02982187
- Testing
- PQ1
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline